12/16/2011

Prana Biotechnology said it has started screening patient participants for a Phase II imaging trial of its experimental Alzheimer's disease drug PBT2. The trial will use PiB-PET imaging and blood tests to determine the effects of the drug.

Full Story:
MarketWire

Related Summaries